Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment DOI Creative Commons
Rongyang Li,

Bing Huang,

Hui Tian

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 12

Published: Jan. 9, 2023

Esophageal cancer (EC) is one of the most life-threatening malignancies worldwide. squamous cell carcinoma (ESCC) dominant subtype, accounting for approximately 90% new incident EC each year. Although multidisciplinary treatment strategies have advanced rapidly, patients with ESCC are often diagnosed at stage and long-term prognosis remains unsatisfactory. In recent decades, immunotherapy, such as immune checkpoint inhibitors (ICIs), tumor vaccines, chimeric antigen receptor T-cell (CAR-T) therapy, has been successfully used in clinical practice a novel therapy treating tumors, bringing hope to patients. However, only small fraction achieved benefits due primary or acquired resistance. Immune evasion plays pivotal role initiation progression ESCC. Therefore, thorough understanding mechanisms by which cells escape from anti-tumor immunity necessary more effective strategy. It widely recognized that closely associated crosstalk between microenvironment (TME). TME dynamic complex comprehensive system including not cellular components but also non-cellular components, influence hallmarks fates outside. Novel immunotherapy targeting tumor-favorable represents promising strategy achieve better therapeutic responses this review, we provide an overview ESCC, mainly focusing on molecular underlie addition, discuss challenges opportunities precision TME.

Language: Английский

Targeting inflammation as cancer therapy DOI Creative Commons
Manni Wang, Siyuan Chen,

Xuemei He

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: March 22, 2024

Abstract Inflammation has accompanied human beings since the emergence of wounds and infections. In past decades, numerous efforts have been undertaken to explore potential role inflammation in cancer, from tumor development, invasion, metastasis resistance tumors treatment. Inflammation-targeted agents not only demonstrate suppress cancer but also improve efficacy other therapeutic modalities. this review, we describe highly dynamic complex inflammatory microenvironment, with discussion on key mediators including cells, cytokines, their downstream intracellular pathways. addition, especially address development highlight action mechanisms inflammation-targeted therapies antitumor response. Finally, summarize results both preclinical clinical studies up date illustrate translation therapies.

Language: Английский

Citations

32
Multifunctional Biomimetic Liposomes with Improved Tumor‐Targeting for TNBC Treatment by Combination of Chemotherapy, Anti‐Angiogenesis and Immunotherapy DOI
Jinshuai Lan, Lixia Chen, Zhe Li

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: May 20, 2024

Triple negative breast cancer (TNBC) featuring high relapses and metastasis shows limited clinical therapeutic efficiency with chemotherapy for the extremely complex tumor microenvironment, especially angiogenesis immunosuppression. Combination of antiangiogenesis immunotherapy holds promise effective inhibition proliferation invasion, while it remains challenging specific targeting drug delivery to tumors metastatic lesions. Here, a multifunctional biomimetic liposome loading Gambogic acid (G/R-MLP) is developed using Ginsenoside Rg3 (Rg3) substitute cholesterol cell membrane coating, which designed increase long-circulating action by low immunogenicity specifically deliver gambogic (GA) site lesions homologous glucose transporter targeting. After G/R-MLP accumulates in primary nodules, synergistically enhances antitumor efficacy GA, effectively suppressing growth lung killing cells, inhibiting migration achieving improving immunity. All all, strategy combining chemotherapy, antiangiogenesis, improves prolonged survival, providing new perspective treatment TNBC.

Language: Английский

Citations

31
Adoptive T cell therapy for solid tumors: current landscape and future challenges DOI Creative Commons
Víctor Albarrán, María San Román, Javier Pozas

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 14, 2024

Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, (TCR) gene-modified cells, with tumor-infiltrating (TILs). The outstanding results CAR-T in some hematologic malignancies have launched investigation ACT patients refractory solid malignancies. However, certain characteristics tumors, such as their antigenic heterogeneity immunosuppressive microenvironment, hamper efficacy antigen-targeted treatments. Other modalities, TIL emerged promising new strategies. has shown safety immunogenic cancers, mainly advanced melanoma, an exciting rationale for its combination checkpoint inhibitors. implementation clinical practice is hindered by several biological, logistic, economic challenges. In this review, we aim summarize current knowledge, available results, potential areas future research regarding use tumors

Language: Английский

Citations

23
Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities DOI Creative Commons

Yujing Qian,

Yujia Yin,

Xiaocui Zheng

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Jan. 7, 2024

Abstract Tumor-associated macrophages (TAMs) are a heterogeneous population that play diverse functions in tumors. Their identity is determined not only by intrinsic factors, such as origins and transcription but also external signals from the tumor microenvironment (TME), inflammatory metabolic reprogramming. Metabolic reprogramming has rendered TAM to exhibit spectrum of activities ranging pro-tumorigenic anti-tumorigenic, closely associated with progression clinical prognosis. This review implicates diversity phenotypes functions, how this heterogeneity been re-evaluated advent single-cell technologies, impact TME on TAMs. We current therapies targeting metabolism offer new insights for TAM-dependent anti-tumor immunotherapy focusing critical role different programs

Language: Английский

Citations

20
Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs DOI Creative Commons

Xiaojun Shi,

Shiyu Pang,

Jiawei Zhou

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: March 9, 2024

Abstract Background Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is one of the causes tumor immune tolerance and failure cancer immunotherapy. Here, we found that bladder (BCa)-derived exosomal circRNA_0013936 could enhance immunosuppressive activity PMN-MDSCs by regulating expression fatty acid transporter protein 2 (FATP2) receptor-interacting kinase 3 (RIPK3). However, underlying mechanism remains largely unknown. Methods BCa-derived exosomes was isolated used for a series experiments. RNA sequencing to identify differentially expressed circRNAs. Western blotting, immunohistochemistry, immunofluorescence, qRT-PCR, ELISA Flow cytometry were performed reveal potential promoting PMN-MDSC. Results CircRNA_0013936 enriched in promote FATP2 inhibit RIPK3 PMN-MDSCs. Mechanistically, promoted inhibited via sponging miR-320a miR-301b, which directly targeted JAK2 CREB1 respectively. Ultimately, significantly functions CD8 + T up-regulating through circRNA_0013936/miR-320a/JAK2 pathway, down-regulating circRNA_0013936/miR-301b/CREB1 pathway Conclusions promotes suppressive immunity circRNA_0013936/miR-301b-3p/CREB1 These findings help find new targets clinical treatment human cancer.

Language: Английский

Citations

20
The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy DOI Creative Commons

Angela Kwok-Fung Lo,

William O. Dawson, Hong Lok Lung

et al.

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: Feb. 25, 2021

Nasopharyngeal carcinoma (NPC) is closely associated with Epstein-Barr virus (EBV) infection. It also characterized by heavy infiltration non-malignant leucocytes. The EBV-encoded latent membrane protein 1 (LMP1) believed to play an important role in NPC pathogenesis virtue of its ability activate multiple cell signaling pathways which collectively promote proliferation and survival, angiogenesis, invasiveness, aerobic glycolysis. LMP1 affects cell-cell interactions, antigen presentation, cytokine chemokine production. Here, we discuss how modulates local immune responses that contribute the establishment tumor microenvironment. We strategies for targeting as a novel therapy EBV-driven malignancies.

Language: Английский

Citations

72
The impact of hypoxia on immune state in cancer DOI
Keywan Mortezaee, Jamal Majidpoor

Life Sciences, Journal Year: 2021, Volume and Issue: 286, P. 120057 - 120057

Published: Oct. 18, 2021

Language: Английский

Citations

70
The interactions of paclitaxel with tumour microenvironment DOI

Ding‐Li Yu,

Zhiping Lou, Fengyun Ma

et al.

International Immunopharmacology, Journal Year: 2022, Volume and Issue: 105, P. 108555 - 108555

Published: Feb. 1, 2022

Language: Английский

Citations

67
Tumor−associated macrophage polarization in the inflammatory tumor microenvironment DOI Creative Commons

Zijuan Zou,

Hongfen Lin,

Mengsen Li

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Feb. 2, 2023

The chronic inflammation of tumor continues to recruit TAMs (tumor−associated macrophages) the TME (tumor microenvironment) and promote polarization. Pro-inflammatory signals polarize macrophages M1 phenotype enhance against pathogens. Tumor inflammatory development changes pro-inflammatory response an anti-inflammatory response, resulting in alteration from M2 progression. Additionally, hypoxia activates HIF (hypoxia-inducible factors) TME, which reprograms support development. Here, we discuss factors that drive phenotypic will help cancer immunotherapy macrophages.

Language: Английский

Citations

41
Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products DOI

Holya A. Lafta,

Ali Hamid AbdulHussein,

Saif A. J. Al-Shalah

et al.

Current Topics in Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 23(12), P. 1104 - 1122

Published: Feb. 1, 2023

Abstract: Tumor-associated macrophages (TAMs) play a pivotal role in the progression and re-sistance of tumors to different anticancer drugs. TAMs can modulate tumor microenvironment (TME) favor immune system exhaustion. The interactions with TME affect function cytotoxic CD8+ T lymphocytes (CTLs) natural killer (NK) cells. Furthermore, induce cancer cell proliferation by releasing some growth factors, such as transforming factor (TGF)-β. have several positive cross-talks other suppressive cells regulatory (Tregs), myeloid-derived suppressor (MDSCs), cancer-associated fibroblasts (CAFs), cells, leading release prolif-eration growth. These also invasion migration angiogenesis, metastasis. inhibition is an intriguing strategy for overcoming resistance suppression Some natural-derived agents melatonin, curcumin, resveratrol, apigenin, flavonoids shown ability TME, including TAMs. adjuvants may be able boost antitumor immunity through modulation This review explains modulatory effects well-known naturally derived on activity these useful suppressing invasion.

Language: Английский

Citations

39